Aft banks on stronger second half as strike and destocking hit first-half result

Aft banks on stronger second half as strike and destocking hit first-half result
Hartley Atkinson says Aft should have a new licensing deal for its Maxigesic pain relief soon. (Image: Aft Pharmaceuticals)
Rebecca Stevenson
Aft Pharmaceuticals is pinning its hopes on a stronger second-half result after a $2.46 million loss for the six months to Sept 30. The New Zealand Exchange (NZX) listed pharmaceutical manufacturer said its result was affected by a doctor strike in South Korea and several large customers reducing stock. These caused a $6.5m hit to product sales and royalties in Aft’s Asian and other international markets, the company said.Sales of its Maxigesic intravenous line were significantly affected by the now-resolved doctors' strike....

More Markets

NZ sharemarket rises ahead of interest rate decision
Markets Market close

NZ sharemarket rises ahead of interest rate decision

The S&P/NZX 50 Index closed at 12,765.24, up 28.18 points or 0.22%.

IkeGPS revenue shows sparks for subscriptions play
Markets

IkeGPS revenue shows sparks for subscriptions play

Despite a $7m net loss, subscription revenue grew 28%.

Ben Moore 12:00pm
My Food Bag profitability up, customer numbers dip
Retail

My Food Bag profitability up, customer numbers dip

Company expects market conditions to remain challenging in the second half.

‘Battle-hardened’ Trade Window eyes growth
Markets

‘Battle-hardened’ Trade Window eyes growth

The customs software minnow has weathered the storm. What next?